Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16449775 | 0.87 | HPGD (0.42) | CA1CA2CA12CA9POLB | |
| SCHEMBL16449772 | 0.78 | KMT2A (0.42) | CA1CA2CA12CA9POLB | |
| SCHEMBL10486780 | 0.75 | CA1 (0.62) | CA1CA2CA12CA9PKM | |
| SCHEMBL11291652 | 0.73 | — | — | |
| SCHEMBL15615373 | 0.73 | — | — | |
| SCHEMBL12708695 | 0.73 | — | — | |
| SCHEMBL2624391 | 0.73 | ALDH1A1 (0.46) | CA1CA2CA12CA9PKM | |
| SCHEMBL22072062 | 0.73 | CA1 (0.43) | CA1CA2CA12CA9PKM | |
| SCHEMBL11450846 | 0.71 | — | — | |
| SCHEMBL4519678 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745335-B2 | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application | BLIRT S.A. (PL) | 2017-08-29 | — | — | US | disclosed |
| US-20170182049-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-20170182049-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-9447136-B2 | Semisynthetic derivatives of Nystatin A1 | BLIRT S.A. (PL) | 2016-09-20 | — | — | US | disclosed |
| US-20150291648-A1 | N-SUBSTITUTED SECOND GENERATION DERIVATIVES OF ANTIFUNGAL ANTIBIOTIC AMPHOTERICIN B AND METHODS OF THEIR PREPARATION AND APPLICATION | BLIRT S.A. (PL) | 2015-10-15 | — | — | US | disclosed |
| US-20150259326-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-09-17 | — | — | US | disclosed |
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | BLIRT S.A. (PL) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259326-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | ING2, GMFG, PLP2 | CA1 429/4885CA2 1473/4885CA12 804/4885 |
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | NPC1, NPC1L1, LSS | CA1 4407/4885CA2 3977/4885CA12 4179/4885 |
| US-20150291648-A1 | N-SUBSTITUTED SECOND GENERATION DERIVATIVES OF ANTIFUNGAL ANTIBIOTIC AMPHOTERICIN B AND METHODS OF THEIR PREPARATION AND APPLICATION | ERG28, LSS, NPC1 | CA1 4780/4885CA2 3831/4885CA12 4088/4885 |
| US-20170182049-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | ING2, GMFG, PLP2 | CA1 429/4885CA2 1473/4885CA12 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.